Fowler’s Syndrome: Causes, Symptoms, and Treatment

Fowler’s syndrome is a condition in which the muscle forming the urethral sphincter fails to relax properly, trapping urine in the bladder and causing chronic urinary retention in young women. First described in the mid-1980s, the condition is named after the neurologist Clare Fowler, who identified a distinctive pattern of abnormal electrical activity in the urethral sphincter muscle that appeared to lock it shut. Despite being a well-documented cause of urinary retention, Fowler’s syndrome remains under-recognized, and many women go years before receiving a correct diagnosis.

What Happens in the Urethral Sphincter

The core problem in Fowler’s syndrome sits in the striated muscle that wraps around the urethra. Normally, when you urinate, the brain signals this muscle to relax so urine can flow out. In women with Fowler’s syndrome, the muscle generates abnormal electrical activity that keeps it in a state of sustained contraction. Needle electrode recordings from the sphincter reveal two signature patterns: complex repetitive discharges and what are called “decelerating bursts,” a distinctive waveform that sounds like a helicopter winding down when played through a loudspeaker. These patterns resemble a rare phenomenon previously labeled “pseudomyotonia” in skeletal muscle and are exceedingly unusual outside the urethral sphincter in this context.¹

The sustained contraction raises the pressure inside the urethra well beyond normal levels. Studies of women with this EMG abnormality show their maximum urethral closure pressure averaging around 103 cm of water, compared to roughly 77 cm of water in women with retention who lack the abnormality.² The sphincter itself also tends to be physically larger. This combination of excessive pressure and increased volume creates an effective seal that the bladder simply cannot overcome, no matter how full it becomes.

Because the bladder keeps filling against a locked sphincter, women with Fowler’s syndrome often develop very large bladder capacities. One case report documented a bladder holding up to 1,200 milliliters, roughly three times a typical volume, with almost no sensation of fullness.³ Over time, the bladder muscle itself can become underactive from chronic overstretching. The resulting picture includes a large, insensitive bladder, a sphincter that won’t open, and a detrusor muscle that has lost some of its ability to contract.⁴

Who Gets It and What Triggers It

Fowler’s syndrome overwhelmingly affects women, typically in their twenties and thirties. The reason it skews so heavily female is not entirely understood, but the condition appears to have a hormonal dimension. A study that recorded sphincter EMG activity in healthy women with no urinary symptoms found that over half showed the same complex repetitive discharges and decelerating bursts at some point during their menstrual cycle, particularly during the mid-luteal phase when progesterone peaks. None showed abnormal activity in the early follicular phase alone.⁵ This finding suggests that the electrical abnormality may exist on a spectrum in premenopausal women, with full-blown Fowler’s syndrome representing one end where the activity becomes persistent and overwhelming enough to block voiding entirely.

Many women can point to a specific event that seemed to set things off. A retrospective study of 62 patients found that abdominopelvic surgery under general anesthesia was the single most common trigger, accounting for about a third of cases.⁶ But the trigger list does not stop at surgery. In that same group, half had unexplained chronic pain syndromes, and about one in five of those women were taking prescription opiates. Researchers have proposed that opioid use may compound the problem by affecting spinal cord pathways involved in bladder control, potentially worsening whatever underlying predisposition these women already have.⁷

Polycystic ovaries turn up frequently in women with Fowler’s syndrome, reinforcing the hormonal connection. Some case series have found polycystic ovaries in a substantial share of patients, even when the women don’t meet full criteria for polycystic ovary syndrome. This association has never been fully explained, but it further supports the idea that the hormonal environment in premenopausal women plays some role in sustaining the abnormal sphincter activity.

What It Feels Like

The hallmark symptom is the inability to urinate or feeling that you can only partially empty your bladder. Some women notice a gradual decline: they void less often, the stream weakens, and they start feeling uncomfortable fullness without the usual urge. Others experience an abrupt onset, sometimes after surgery or an illness, where they suddenly cannot void at all and end up in an emergency department with a catheter.

What makes Fowler’s syndrome particularly insidious is the loss of bladder sensation. Many women don’t feel the classic desperate urge to urinate even when their bladder is enormously distended. This blunted awareness can delay recognition. A woman who is retaining 500 or 800 milliliters of urine after each attempt to void may not realize something is seriously wrong because the discomfort she feels is vague, more like bloating or pelvic pressure than a recognizable urinary problem.

Recurrent urinary tract infections are a common secondary problem, both from the stagnant urine left in the bladder and from the catheters used to manage the retention. The case report of a young woman whose bladder capacity reached 1,200 mL described recurrent infections once a suprapubic catheter was placed.³ For many women, managing these infections becomes a frustrating secondary battle layered on top of the retention itself.

Why Diagnosis Takes So Long

Fowler’s syndrome is probably more common than diagnostic statistics suggest, partly because many clinicians don’t think to look for it. Urinary retention in young women is itself unusual enough that some healthcare providers initially attribute symptoms to psychological causes, medication side effects, or simple constipation. The condition has been described as “often forgotten” in the medical literature, and the diagnostic delay can stretch for years.⁴

There is no single blood test or imaging scan that clinches the diagnosis. Instead, the workup involves a combination of clinical history, urodynamic testing, and sphincter EMG. Urodynamics will show the large bladder capacity, elevated urethral closure pressure, and detrusor underactivity. The EMG, performed with a needle electrode placed into the urethral sphincter, confirms the characteristic decelerating bursts and complex repetitive discharges.⁸ Not every center has a neurophysiologist trained to perform and interpret this specific test, which is one reason referrals to specialized units are often necessary.

Another complicating factor is overlap with other conditions. In the retrospective study of 62 patients, about a quarter had functional neurological symptoms on top of their urinary retention.⁶ This comorbidity can muddy the diagnostic picture. If a woman already carries a diagnosis of a functional neurological disorder, her urinary symptoms may be assumed to fall under the same umbrella rather than being recognized as a distinct sphincter abnormality requiring targeted treatment.

Sacral Neuromodulation

The primary treatment that has been shown to restore voiding in women with Fowler’s syndrome is sacral neuromodulation, often called sacral nerve stimulation. This involves implanting a small device, similar to a pacemaker, near the sacral nerves at the base of the spine. The device delivers continuous low-level electrical pulses that appear to override the abnormal sphincter activity and allow the bladder to empty. It is FDA-approved for this indication.⁹

The results have been encouraging but not without caveats. In an early series, all twelve women who received a permanent implant experienced a return of voiding.¹⁰ A five-year follow-up of 26 implanted patients found that about three-quarters were still voiding spontaneously, with a mean post-void residual of 75 mL and a healthy flow rate. Two women had their stimulators deactivated because of pregnancy, not failure.¹¹ A longer-term study spanning twelve years reported a success rate of about 71%, with mean residual urine dropping from over 400 mL to around 28 mL in those who responded.⁴

The trade-off is that the hardware requires maintenance. Revision rates have been reported as high as 54% over several years, with the most common problems being loss of effectiveness over time, discomfort around the implant, and leg pain.⁴ That does not mean the device stops working permanently in most cases; revisions often restore function. But it does mean that women considering implantation should expect the possibility of additional procedures over the years. Pregnancy is another practical consideration, since the stimulator is typically deactivated during pregnancy as a precaution.

Botulinum Toxin Injections

For women who cannot access sacral neuromodulation, or who want to try a less invasive option first, injections of botulinum toxin into the urethral sphincter have emerged as a promising alternative. The logic is straightforward: if the sphincter is locked in contraction, temporarily weakening the muscle with a targeted injection should let it relax enough for urine to pass.

An open-label study of ten women with Fowler’s syndrome found that sphincter injections of onabotulinumtoxinA improved symptom scores substantially and roughly doubled their peak urine flow rate. Four of the five women who had been in complete retention were able to void spontaneously within ten weeks, and the average residual urine dropped from 260 mL to 89 mL. No serious side effects occurred, and seven of the ten women opted to return for repeat injections.¹²

A larger study evaluating the periurethral injection approach found that about two-thirds of the 33 individuals treated responded to the injections, and the response tended to be stronger in women who started with higher baseline urethral pressures. Side effects occurred after about 12% of injections, but they were mild and short-lived. Women who responded could receive repeat injections at a median interval of roughly four months, and efficacy held up across multiple rounds without safety concerns.¹³ A separate cohort treated during the COVID-19 pandemic confirmed similar results: about two-thirds reported improvement, with six patients becoming catheter-free entirely. Transient stress incontinence occurred in some women but resolved within two weeks.¹⁴

The obvious drawback is that the effect wears off. Unlike sacral neuromodulation, which provides continuous stimulation, botulinum toxin needs to be readministered every few months. This can suit some women well, particularly those who want to avoid surgery or who are planning a pregnancy in the near future. For others, the cycle of injections becomes burdensome, and they eventually pursue the implant.

Intermittent Self-Catheterization

Before either of these treatments became available, and still today for women awaiting them, the main management strategy is clean intermittent self-catheterization. This involves inserting a thin catheter through the urethra several times a day to drain the bladder. It works in the practical sense of preventing dangerous overdistension and kidney damage, but it is not a treatment for the underlying sphincter problem. It manages the consequences.

Many women adapt to self-catheterization and manage it effectively for years. Others find it difficult physically or emotionally, especially given that the typical patient is a young woman who may have to catheterize at work, school, or social settings. Some cannot tolerate it at all. In the case report of the young woman with a 1,200 mL bladder, intolerance of self-catheterization led to placement of a suprapubic catheter, which then brought its own problems with recurrent infections.³ That patient eventually had her voiding restored by sacral neuromodulation.

The Psychological Weight

Living with Fowler’s syndrome takes a significant toll beyond the bladder. A recent study of women with urinary retention reported that 97% had psychiatric or psychological comorbidities. Current depression was present in 77%, current anxiety in 78%, and post-traumatic stress disorder in 32%. Functional neurological symptoms were found in over half, and childhood trauma was reported in 35%.¹⁵

These numbers raise an important chicken-and-egg question. Some of this psychological burden likely predates the urinary condition, and the overlap with chronic pain syndromes and functional neurological disorders suggests shared vulnerability pathways. But a great deal of it is also clearly reactive. Being a young woman unable to urinate normally, dependent on catheters, dealing with recurrent infections, and often not believed or correctly diagnosed for years is inherently distressing. The frustration of having a real physiological abnormality mistaken for a psychological problem only deepens the psychological harm.

Overlapping Conditions

Fowler’s syndrome rarely exists in isolation. A patient-led phenotyping study of 265 women found wide-ranging comorbidities spanning connective tissue disorders, autoimmune conditions, and autonomic dysfunction. These included conditions like Ehlers-Danlos syndrome, Raynaud’s disease, lupus, postural orthostatic tachycardia syndrome, and various forms of arthritis.¹⁶ This clustering of conditions suggests that Fowler’s syndrome may be one manifestation of a broader tendency toward dysregulation of muscle, nerve, or connective tissue function in susceptible individuals.

The presence of these overlapping conditions complicates treatment. A woman with Ehlers-Danlos syndrome may have tissue-healing concerns that affect surgical planning. A woman with chronic pain who is taking opioids may find that her pain medication is worsening the very retention it indirectly helps her cope with. These layered problems are part of why specialized, multidisciplinary care has become a focus in recent efforts to improve outcomes.

Multidisciplinary Care Models

Because Fowler’s syndrome sits at the intersection of urology, neurology, gynecology, pain medicine, and psychology, a growing number of centers are adopting team-based approaches. A multidisciplinary team model at Beaumont Hospital in Ireland reported that coordinated assessment improved clinical confidence in diagnosis, gave patients earlier access to supportive services, reduced psychological distress, and enabled better shared decision-making around invasive interventions like sacral neuromodulation.¹⁷

A separate initiative produced what its authors call the “Fife Definition” of chronic idiopathic urinary retention, along with a new framework for assessment and nonsurgical management that draws on both clinical evidence and the lived experience of patients.¹⁸ The inclusion of patient voices in shaping these frameworks reflects a broader shift in how the condition is managed. For years, women with Fowler’s syndrome have organized online and advocated for better recognition. That advocacy appears to be gaining traction in clinical circles, though access to specialized care remains uneven depending on geography.

What Hormones Have to Do With It

The hormonal angle remains one of the more fascinating and unresolved aspects of Fowler’s syndrome. The finding that more than half of healthy, asymptomatic women showed the same type of abnormal sphincter EMG activity during the luteal phase of their cycle suggests that female reproductive hormones normally exert some influence on urethral sphincter excitability.⁵ In most women, the activity is transient and never severe enough to affect voiding. In women who develop Fowler’s syndrome, something tips the balance so that the activity becomes sustained.

The frequent co-occurrence of polycystic ovaries fits this pattern, since polycystic ovaries are associated with altered hormonal profiles including elevated androgens and disrupted progesterone cycling. Whether the hormonal abnormality causes the sphincter dysfunction, or whether both are downstream effects of some shared underlying vulnerability, is still an open question. Researchers have also speculated about the role of endogenous opioids, the body’s own pain-modulating chemicals, which interact with the same spinal cord circuits involved in bladder control. The hypothesis that an upregulation of spinal cord enkephalins may contribute to Fowler’s syndrome remains a working theory, supported by the observation that exogenous opioid use seems to compound functional voiding problems in susceptible women.⁷

Understanding these hormonal and neurochemical connections matters practically, not just academically. If a woman with Fowler’s syndrome is prescribed opioid medication for another condition, her clinicians should be aware that this could worsen her urinary retention. Similarly, hormonal treatments for other gynecological conditions might, in theory, influence sphincter behavior, though this has not been tested in clinical trials specific to Fowler’s syndrome. The science here is still catching up with the clinical observations.